CRIS
Curis, Inc. NASDAQ Listed Aug 1, 2000$0.58
Mkt Cap $7.6M
52w Low $0.49
3.3% of range
52w High $3.13
50d MA $0.73
200d MA $1.21
P/E (TTM)
-1.0x
EV/EBITDA
-3.9x
P/B
14.3x
Debt/Equity
0.3x
ROE
-138.8%
P/FCF
-4.8x
RSI (14)
—
ATR (14)
—
Beta
3.14
50d MA
$0.73
200d MA
$1.21
Avg Volume
416.1K
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, which is in a Phase 1/2 clinical trial for the treatment of non-hodgkin lymphomas, and acute myeloid leukemia and myelodysplastic syndromes; and CI-8993, a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with MYC-altered diffuse large B-cell lymphoma; CA-170, an oral small molecule drug candidate for treating patients with advanced solid tumors and lymphomas; and CA-327, a pre-investigational new drug stage oncology drug candidate. It has collaboration agreement with F. Hoffmann-La Roche Ltd. and Genentech Inc. for the development and commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway inhibitor for the treatment of advanced basal cell carcinoma; and with Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.
Building C · Lexington, MA 02421 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 19, 2026 | AMC | -0.44 | -0.50 | -14.7% | 0.76 | +0.7% | +1.9% | -2.3% | -5.5% | -7.5% | -23.4% | — |
| Nov 6, 2025 | AMC | -0.62 | -0.49 | +21.0% | 1.46 | -7.5% | -10.3% | -10.3% | -14.4% | -15.8% | -22.6% | — |
| Aug 5, 2025 | AMC | -1.99 | -0.68 | +65.8% | 1.67 | +0.6% | +0.0% | +3.0% | +2.4% | -2.4% | -1.2% | — |
| May 6, 2025 | AMC | -1.14 | -1.25 | -9.6% | 2.19 | -0.9% | -5.9% | -4.1% | -13.7% | -10.5% | -3.2% | — |
| Mar 31, 2025 | AMC | -1.36 | -1.25 | +8.1% | 2.10 | +1.0% | -30.5% | -29.5% | -36.7% | -41.4% | -44.8% | — |
| Nov 14, 2024 | AMC | -1.88 | -1.70 | +9.6% | 3.98 | +0.0% | -0.8% | -4.5% | -4.8% | -7.0% | +3.0% | — |
| Aug 1, 2024 | AMC | -1.70 | -2.03 | -19.4% | 4.94 | +1.2% | +1.2% | -2.6% | -2.8% | -10.7% | -8.9% | — |
| May 7, 2024 | AMC | -1.94 | -2.05 | -5.7% | 16.20 | +3.7% | +0.9% | +1.9% | -3.0% | -3.3% | -3.1% | — |
| Feb 8, 2024 | AMC | -1.91 | -2.03 | -6.3% | 10.65 | -3.0% | -2.3% | +0.7% | -4.8% | -3.4% | -4.0% | — |
| Dec 21, 2023 | AMC | — | -2.58 | — | 12.69 | -1.3% | +8.6% | +10.7% | +11.1% | +9.5% | +0.5% | — |
| Nov 2, 2023 | AMC | -2.32 | -2.13 | +8.2% | 4.51 | +1.1% | +1.3% | +18.4% | +20.4% | +37.7% | +39.5% | — |
| Aug 3, 2023 | AMC | -2.40 | -2.40 | +0.0% | 15.42 | -0.5% | -8.8% | -20.6% | -16.3% | -14.9% | -15.9% | — |
| May 4, 2023 | AMC | -2.20 | -2.40 | -9.1% | 16.76 | -4.5% | -3.9% | -4.6% | -0.8% | +3.5% | +8.6% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.76 | $0.76 | +0.7% | +1.9% | -2.3% | -5.5% | -7.5% | -23.4% |
| Mar 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.32 | $2.30 | -0.9% | -9.5% | -37.1% | -36.2% | -42.7% | -47.0% |
| Dec 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.14 | $4.08 | -1.4% | -4.3% | -8.0% | -10.1% | -13.8% | -15.9% |
| Nov 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.98 | $3.98 | +0.0% | -0.8% | -4.5% | -4.8% | -7.0% | +3.0% |
| Nov 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.28 | $4.38 | +2.3% | -2.3% | +1.2% | +3.3% | -1.9% | +1.6% |
| Aug 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.48 | $5.48 | +0.0% | -9.9% | -8.8% | -12.2% | -12.4% | -19.5% |
| May 15 | Truist | Maintains | Buy → Buy | — | $15.69 | $15.34 | -2.2% | -17.1% | -19.7% | -24.8% | -33.0% | -31.2% |
| May 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $15.69 | $15.34 | -2.2% | -17.1% | -19.7% | -24.8% | -33.0% | -31.2% |
| May 8 | HC Wainwright& Co. | Maintains | Buy → Buy | — | $16.20 | $16.80 | +3.7% | +0.9% | +1.9% | -3.0% | -3.3% | -3.1% |
| May 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $16.20 | $16.80 | +3.7% | +0.9% | +1.9% | -3.0% | -3.3% | -3.1% |
| Feb 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.65 | $10.33 | -3.0% | -2.3% | +0.7% | -4.8% | -3.4% | -4.0% |
| Sep 29 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.60 | $6.00 | -21.1% | -13.3% | -31.6% | -29.2% | -34.1% | -34.7% |
| Sep 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.61 | $8.80 | +2.2% | -11.7% | -23.5% | -39.6% | -37.5% | -41.8% |
| Sep 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.01 | $8.91 | -1.1% | -4.9% | -6.1% | -4.4% | -15.6% | -26.9% |
| Sep 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Sep 7 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $10.62 | $10.52 | -0.9% | -0.6% | -0.6% | -3.9% | -3.6% | -4.1% |
| Sep 6 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $11.13 | $11.76 | +5.7% | -4.6% | -5.1% | -5.1% | -8.3% | -8.0% |
| Aug 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $15.42 | $15.34 | -0.5% | -8.8% | -20.6% | -16.3% | -14.9% | -15.9% |
| Aug 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $15.89 | $15.80 | -0.6% | -3.0% | -11.5% | -22.9% | -18.8% | -17.4% |
| Jul 11 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $17.40 | $17.24 | -0.9% | -3.4% | +0.0% | -4.2% | -7.8% | -9.2% |
| Jul 10 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $16.20 | $16.70 | +3.1% | +7.4% | +3.8% | +7.4% | +2.9% | -0.9% |
| Jul 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $16.88 | $17.10 | +1.3% | -4.0% | +3.1% | -0.4% | +3.1% | -1.2% |
| Jul 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $16.41 | $15.00 | -8.6% | +2.9% | -1.3% | +6.0% | +2.4% | +6.0% |
| May 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $16.76 | $16.00 | -4.5% | -3.9% | -4.6% | -0.8% | +3.5% | +8.6% |
| Nov 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $14.44 | $16.00 | +10.8% | +13.6% | +20.5% | +24.2% | +26.2% | +23.9% |
| Nov 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $15.60 | $15.40 | -1.3% | -7.4% | +5.1% | +11.5% | +15.0% | +16.9% |
| Apr 5 | Raymond James | Downgrade | Outperform → Market Perform | — | $32.40 | $32.80 | +1.2% | -7.4% | -9.3% | -9.9% | -11.1% | -18.5% |
| Apr 5 | B. Riley Securities | Maintains | Buy → Buy | — | $32.40 | $32.80 | +1.2% | -7.4% | -9.3% | -9.9% | -11.1% | -18.5% |
| Apr 4 | Raymond James | Downgrade | Outperform → Market Perform | — | $48.60 | $32.60 | -32.9% | -33.3% | -38.3% | -39.5% | -39.9% | -40.7% |
| Apr 4 | B. Riley Securities | Maintains | Buy → Buy | — | $48.60 | $32.60 | -32.9% | -33.3% | -38.3% | -39.5% | -39.9% | -40.7% |
| Oct 13 | Raymond James | Maintains | Outperform → Outperform | — | $150.80 | $156.80 | +4.0% | +0.4% | +0.7% | -3.8% | -1.5% | +0.8% |
| Mar 25 | B. Riley Securities | Maintains | Buy → Buy | — | $206.20 | $206.00 | -0.1% | +14.6% | +10.7% | +9.2% | +10.6% | +9.8% |
| Mar 25 | B. Riley FBR | Maintains | Buy → Buy | — | $206.20 | $206.00 | -0.1% | +14.6% | +10.7% | +9.2% | +10.6% | +9.8% |
| Jan 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $235.80 | $242.00 | +2.6% | +8.6% | +4.7% | -2.0% | -5.9% | -7.0% |
| Jan 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $210.80 | $211.20 | +0.2% | +11.9% | +21.4% | +17.1% | +9.6% | +5.2% |
| Dec 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $28.80 | $109.40 | +279.9% | +354.9% | +434.0% | +460.8% | +447.9% | +469.4% |
| Dec 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $37.60 | $38.20 | +1.6% | -23.4% | +248.4% | +309.0% | +329.5% | +319.7% |
| Nov 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $27.00 | $28.00 | +3.7% | +1.5% | +1.5% | +6.7% | +7.4% | +13.3% |
| Jul 17 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $23.60 | $24.60 | +4.2% | +5.1% | +8.1% | +17.8% | +16.1% | +10.2% |
| May 7 | Baird | Maintains | Outperform → Outperform | — | $50.19 | $51.65 | +2.9% | +1.0% | -2.4% | +1.2% | +3.3% | +4.3% |
| May 6 | Baird | Maintains | Outperform → Outperform | — | — | — | — | — | — | — | — | — |
| Oct 24 | Guggenheim | Maintains | Buy → Buy | — | $157.00 | $170.00 | +8.3% | +5.1% | +4.5% | +1.3% | -0.6% | +1.9% |
| Mar 1 | SunTrust Robinson Humphrey | Maintains | Buy → Buy | — | $137.00 | $141.00 | +2.9% | +9.5% | +21.2% | +30.7% | +28.5% | +29.2% |
| Aug 11 | FBR Capital | Maintains | Outperform → Outperform | — | $254.00 | $258.00 | +1.6% | +2.4% | +2.8% | +13.4% | +10.6% | +15.0% |
| Jun 1 | Baird | Maintains | Outperform → Outperform | — | $337.00 | $339.00 | +0.6% | -1.8% | +3.9% | +3.9% | +1.2% | +4.5% |
| May 31 | Baird | Maintains | Outperform → Outperform | — | — | — | — | — | — | — | — | — |
| May 9 | Oppenheimer | Maintains | Outperform → Outperform | — | $194.00 | $191.00 | -1.5% | +3.6% | +6.2% | +3.1% | +2.1% | -1.5% |
| May 8 | Oppenheimer | Maintains | Outperform → Outperform | — | $201.00 | $202.00 | +0.5% | -3.5% | +0.0% | +2.5% | -0.5% | -1.5% |
| Dec 6 | Wedbush | Maintains | Outperform → Outperform | — | $338.00 | $362.00 | +7.1% | +1.5% | -17.5% | -18.0% | -27.2% | -25.1% |
| Dec 5 | Wedbush | Maintains | Outperform → Outperform | — | $332.00 | $332.00 | +0.0% | +1.8% | +3.3% | -16.0% | -16.6% | -25.9% |
No insider trades available.
8-K
Curis, Inc. -- 8-K Filing
Curis Inc. faces delisting from Nasdaq Capital Market on May 6, 2026, due to failing the minimum bid price rule, though the company plans to appeal the determination.
May 1
8-K
Unknown — 8-K Filing
Curis's emavusertib showed clinical progress in primary CNS lymphoma, potentially expanding its market opportunity beyond initial indications and validating the IRAK4/FLT3 inhibitor approach.
Mar 19
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
Curis Inc. approved a substantial equity incentive pool (25M shares) for executive compensation, increasing dilution risk for existing shareholders and signaling significant executive retention/motivation efforts ahead.
Mar 17
8-K
Curis Inc -- 8-K Filing
Curis Inc faces potential delisting risks from Nasdaq, creating uncertainty about the company's continued public trading status and investor liquidity.
Feb 9
Data updated apr 25, 2026 3:14am
· Source: massive.com